Q9989: Ustekinumab, for intravenous injection, 1 mg
Q9989 is a HCPCS Level II code for ustekinumab, for intravenous injection, 1 mg. It belongs to the Temporary Codes section. It was terminated on December 31, 2017 and is not valid on new claims.
This code has been terminated
CMS terminated Q9989 on December 31, 2017. It stays in the file as history: a claim you are auditing from before that date may legitimately carry it, but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q9989
- Long descriptor
- Ustekinumab, for intravenous injection, 1 mg
- Short descriptor
- Ustekinumab, iv inject,1 mg
- Added
- July 1, 2017
- Terminated
- December 31, 2017
- BETOS
- O1E
- Pricing indicator
- 51: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Drugs.
Codes adjacent to Q9989
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If Q9989 is not quite right, the correct code is very often within a few positions of it.
- Q9981Rolapitant, oral, 1 mgterminated
- Q9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries
- Q9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
- Q9984Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mgterminated
- Q9985Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mgterminated
- Q9986Injection, hydroxyprogesterone caproate, (makena), 10 mgterminated
- Q9987Pathogen(s) test for plateletsterminated
- Q9988Platelets, pheresis, pathogen-reduced, each unitterminated
- Q9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
- Q9992Injection, buprenorphine extended-release (sublocade), greater than 100 mg
- Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgterminated
- Q9994In-line cartridge containing digestive enzyme(s) for enteral feeding, eachterminated
- Q9995Injection, emicizumab-kxwh, 0.5 mgterminated
- Q9996Injection, ustekinumab-ttwe (pyzchiva), subcutaneous, 1 mg
- Q9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg
- Q9998Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg